Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087958 · ClinicalTrials.gov registry record · Phase 2
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT00087958 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 168 participants.
The verdict
NCT00087958, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
Interventions
- DRUG XRP9881
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2004-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087958
The ClinicalTrials.gov registry entry for NCT00087958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XRP9881 is the first listed.
NCT00087958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087958 about?
NCT00087958 is a clinical study titled "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment". The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
What is the current status of trial NCT00087958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2004-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00087958?
The interventions under investigation include: XRP9881 (DRUG).
Who is sponsoring clinical trial NCT00087958?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.